Nimotuzumab in Children With HGG

Summary

Determination of efficiency of nimotuzumab in children with high grade glioma.

Conditions

• High Grade Glioma

Sponsors & Collaborators

• Children's Medical Hospital, University of Bonn, Germany

  collaborator OTHER

• University of Wuerzburg

  collaborator OTHER

• University of Bonn

  collaborator OTHER

• Dept. of Statistics, University of Dortmund, Germany

  collaborator OTHER

• CRM Biometrics GmbH

  collaborator INDUSTRY

• Heinrich-Heine University, Duesseldorf

  collaborator OTHER

• University Hospital Augsburg

  collaborator OTHER

• Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany

  collaborator OTHER

• Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany

  collaborator OTHER

• Children's Medical Hospital, Medical School Hannover, Hannover, Germany

  collaborator UNKNOWN

• Children's Medical Hospital, University of Essen, Essen, Germany

  collaborator OTHER

• Dept. of Neuropediatrics and Muscle Disorders, University of Freiburg, Germany

  collaborator OTHER

• University of Cologne

  collaborator OTHER

• Universitätsklinikum Hamburg-Eppendorf

  collaborator OTHER

• University of Regensburg

  collaborator OTHER

• Oncoscience AG

  lead INDUSTRY

Principal Investigators

• Udo Bode, Prof. MD · University Bonn

Eligibility

Min Age

3 Years

Max Age

20 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2004-06-30

Completion

2007-02-28

Countries

• Germany

Study Locations